BioCentury
ARTICLE | Clinical News

KN035: Ph I start

December 2, 2016 9:51 PM UTC

The partners said they plan to begin a clinical trial "shortly" after FDA approved an IND for KN035. The open-label, U.S. Phase I trial will evaluate 1, 2.5, 5 and 10 mg/kg subcutaneous KN035 given we...